Athira Pharma, Inc. Stock News

Does Athira Pharma, Inc. (ATHA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive

Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer's disease Com

BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc.  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal healt

Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Athira Pharma, Inc. (ATHA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i

BOTHELL, Wash., May 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health a

Athira Pharma, Inc. (ATHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BOTHELL, Wash., March 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health

HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS HGF/MET small molecule positive modulator provides neuroprotecti

Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration

BOTHELL, Wash., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health

Data supports neuroprotective and disease modifying potential in models of Parkinson's disease and diabetic neuropathy Data supports neuroprotective and disease modifying potential in models of Parkin

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie

Athira Pharma's stock has sold off some months ago on its Alzheimer's drug candidate Fosgonimeton not meeting a primary endpoint in a randomized Phase 2 trial. The monotherapy arm did show remarkable